stock-detail (LOXO)

Oncology Corporate Profile

Company Description

This company does not have any commercial products

This company does not have any pipeline products

Recent News Headlines

4/23/2017 12:18 pm

4/23/2017 12:18 pm

4/23/2017 12:18 pm

4/23/2017 12:18 pm

4/10/2017 12:17 pm

Loxo Oncology Announces Proof of Concept Clinical Data for Larotrectinib in TRK Fusion Glioblastoma Presented at the AACR Annual Meeting 2017

3/31/2017 08:03 pm

[GlobeNewswire] - STAMFORD, Conn., March 31, 2017-- Loxo Oncology, Inc., a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced ...

Loxo Oncology Announces Larotrectinib Pan-TRK IHC Companion Diagnostic Collaboration with Ventana Medical Systems, Inc., a member of the Roche Group

3/20/2017 10:04 am

[GlobeNewswire] - STAMFORD, Conn., March 20, 2017-- Loxo Oncology, Inc., a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced ...

Loxo reports 4Q loss

3/7/2017 11:05 am

Loxo reports 4Q loss

3/7/2017 11:05 am

Loxo Oncology Reports Fourth Quarter and Year-End 2016 Financial Results

3/7/2017 11:04 am

[GlobeNewswire] - STAMFORD, Conn., March 07, 2017-- Loxo Oncology, Inc., a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today reported ...

Loxo Oncology to Present at Cowen and Company 37th Annual Health Care Conference

3/1/2017 11:04 am

[GlobeNewswire] - STAMFORD, Conn., March 01, 2017-- Loxo Oncology, Inc., a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced ...

Loxo Oncology to Announce Fourth Quarter and Year-End 2016 Financial Results

2/28/2017 11:04 am

[GlobeNewswire] - STAMFORD, Conn., Feb. 28, 2017-- Loxo Oncology, Inc., a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, will announce financial ...

Loxo Oncology Announces Completion of Clinical Trial Enrollment for Larotrectinib NDA Primary Efficacy Analysis

2/21/2017 11:04 am

[GlobeNewswire] - STAMFORD, Conn., Feb. 21, 2017-- Loxo Oncology, Inc., a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced ...

Purcell Julie & Lefkowitz LLP is Investigating Loxo Oncology, Inc. for Potential Breaches of Fiduciary Duty by its Board of Directors

2/8/2017 10:04 pm

[Accesswire] - NEW YORK, NY / ACCESSWIRE / February 8, 2017 / Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary ...

Loxo Oncology Announces the Closing of its Follow-On Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

1/10/2017 09:03 pm

[GlobeNewswire] - STAMFORD, Conn., Jan. 10, 2017-- Loxo Oncology, Inc., a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced ...